ELAN
Elanco Animal Health Incorporated NYSE Listed Sep 20, 2018$24.22
+3.55%
vs $23.39
Mkt Cap $12.0B
52w Low $13.33
80.6% of range
52w High $26.84
50d MA $22.98
200d MA $22.62
P/E (TTM)
-51.5x
EV/EBITDA
22.8x
P/B
1.8x
Debt/Equity
0.6x
ROE
-3.5%
P/FCF
42.3x
RSI (14)
52.30
ATR (14)
$1.07
Beta
1.88
50d MA
$22.98
200d MA
$22.62
Avg Volume
7.0M
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
2500 Innovation Way · Greenfield, IN 46140 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | BMO | 0.11 | 0.13 | +18.2% | 26.38 | +0.7% | +1.7% | -2.4% | +0.8% | -1.2% | -4.6% | — |
| Nov 5, 2025 | BMO | 0.13 | 0.19 | +46.2% | 21.60 | +0.6% | -0.4% | -0.1% | +3.6% | +2.6% | -3.5% | — |
| Aug 7, 2025 | BMO | 0.20 | 0.26 | +30.0% | 16.48 | +0.3% | +1.2% | +2.6% | +1.9% | +2.2% | +1.1% | — |
| May 7, 2025 | BMO | 0.31 | 0.37 | +19.4% | 12.01 | +0.6% | +2.2% | -2.6% | +7.2% | +1.6% | -1.1% | — |
| Feb 25, 2025 | BMO | 0.16 | 0.14 | -12.5% | 10.70 | +1.5% | +4.0% | -1.9% | +2.3% | +1.3% | -4.5% | — |
| Nov 7, 2024 | BMO | 0.12 | 0.13 | +8.3% | 14.50 | -1.5% | -3.0% | +1.4% | -1.1% | +0.5% | -1.1% | — |
| Aug 8, 2024 | BMO | 0.24 | 0.30 | +25.0% | 12.99 | -0.6% | +0.4% | +0.4% | +6.5% | +1.0% | +3.6% | — |
| May 8, 2024 | BMO | 0.27 | 0.34 | +24.1% | 16.89 | -0.4% | +1.8% | -1.2% | +0.0% | +0.4% | -0.2% | — |
| Feb 26, 2024 | BMO | 0.10 | 0.08 | -20.0% | 16.26 | +1.8% | +1.2% | -3.2% | -0.3% | +0.9% | +0.9% | — |
| Nov 7, 2023 | BMO | 0.12 | 0.18 | +50.0% | 10.70 | +0.0% | +1.4% | -5.4% | +4.1% | -1.2% | +7.5% | — |
| Aug 7, 2023 | BMO | 0.05 | 0.18 | +260.0% | 12.12 | +0.2% | +2.8% | -1.5% | -0.4% | -0.4% | -1.4% | — |
| May 9, 2023 | BMO | 0.29 | 0.45 | +55.2% | 9.31 | +1.4% | -3.3% | -2.3% | -2.5% | +3.9% | -4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $26.38 | $26.56 | +0.7% | +1.7% | -2.4% | +0.8% | -1.2% | -4.6% |
| Feb 25 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $26.38 | $26.56 | +0.7% | +1.7% | -2.4% | +0.8% | -1.2% | -4.6% |
| Feb 24 | Leerink Partners | Maintains | Outperform → Outperform | — | $24.75 | $24.06 | -2.8% | +6.6% | +1.7% | -2.4% | +0.8% | -1.2% |
| Feb 19 | JP Morgan | Maintains | Overweight → Overweight | — | $24.78 | $25.04 | +1.0% | +1.7% | -0.9% | -0.9% | +6.6% | +1.7% |
| Jan 22 | Piper Sandler | Upgrade | Neutral → Overweight | — | $24.30 | $25.21 | +3.7% | +2.5% | -2.0% | +1.1% | -0.2% | -2.0% |
| Dec 18 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $22.08 | $22.30 | +1.0% | +0.0% | +1.0% | +0.0% | -0.4% | +0.7% |
| Nov 6 | UBS | Maintains | Buy → Buy | — | $21.60 | $21.74 | +0.6% | -0.4% | -0.1% | +3.6% | +2.6% | -3.5% |
| Oct 20 | UBS | Maintains | Buy → Buy | — | $21.42 | $21.59 | +0.8% | +1.4% | -0.5% | +0.1% | +0.6% | +1.3% |
| Oct 7 | JP Morgan | Upgrade | Neutral → Overweight | — | $20.66 | $21.12 | +2.2% | -1.0% | -0.5% | -1.3% | -1.5% | +1.4% |
| Sep 24 | Stifel | Maintains | Buy → Buy | — | $18.54 | $19.11 | +3.1% | +1.1% | +0.9% | +3.6% | +0.0% | +2.7% |
| Aug 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $16.67 | $17.00 | +2.0% | +2.6% | +1.9% | +2.2% | +1.1% | -0.2% |
| Aug 8 | UBS | Maintains | Buy → Buy | — | $16.48 | $16.53 | +0.3% | +1.2% | +2.6% | +1.9% | +2.2% | +1.1% |
| Jul 23 | UBS | Maintains | Buy → Buy | — | $14.93 | $15.12 | +1.3% | +0.6% | -2.2% | +1.6% | -2.3% | -1.3% |
| Jul 17 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $14.51 | $14.95 | +3.0% | +3.1% | -1.2% | -0.7% | +1.7% | +0.6% |
| Jul 2 | Stifel | Maintains | Buy → Buy | — | $14.43 | $14.66 | +1.6% | +2.0% | -0.5% | -1.2% | +1.9% | +0.2% |
| Jun 26 | William Blair | Upgrade | Market Perform → Outperform | — | $13.76 | $14.21 | +3.3% | +3.9% | -0.1% | -0.1% | +1.1% | +2.0% |
| May 19 | Stifel | Maintains | Buy → Buy | — | $12.92 | $12.74 | -1.4% | +2.3% | -1.1% | -3.5% | +0.4% | -0.1% |
| May 8 | Stifel | Maintains | Buy → Buy | — | $12.01 | $12.08 | +0.6% | +2.2% | -2.6% | +7.2% | +1.6% | -1.1% |
| Apr 14 | Stifel | Maintains | Buy → Buy | — | $8.62 | $8.82 | +2.3% | +0.7% | -5.1% | -1.7% | +4.2% | +0.5% |
| Mar 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $10.85 | $10.68 | -1.6% | -0.2% | +2.9% | -3.1% | -7.0% | +3.5% |
| Feb 26 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.70 | $10.86 | +1.5% | +4.0% | -1.9% | +2.3% | +1.3% | -4.5% |
| Feb 26 | Barclays | Maintains | Overweight → Overweight | — | $10.70 | $10.86 | +1.5% | +4.0% | -1.9% | +2.3% | +1.3% | -4.5% |
| Feb 26 | UBS | Maintains | Buy → Buy | — | $10.70 | $10.86 | +1.5% | +4.0% | -1.9% | +2.3% | +1.3% | -4.5% |
| Feb 26 | Stifel | Maintains | Buy → Buy | — | $10.70 | $10.86 | +1.5% | +4.0% | -1.9% | +2.3% | +1.3% | -4.5% |
| Feb 21 | Stifel | Maintains | Buy → Buy | — | $11.13 | $11.19 | +0.5% | -1.0% | +0.8% | -3.7% | +4.0% | -1.9% |
| Jan 29 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $12.17 | $12.14 | -0.2% | +1.0% | +1.5% | -3.5% | -2.6% | -1.8% |
| Jan 7 | Stifel | Maintains | Buy → Buy | — | $11.92 | $11.89 | -0.3% | -1.0% | -2.1% | -1.0% | +2.4% | +0.0% |
| Nov 8 | Barclays | Maintains | Overweight → Overweight | — | $14.50 | $14.28 | -1.5% | -3.0% | +1.4% | -1.1% | +0.5% | -1.1% |
| Oct 28 | Barclays | Maintains | Overweight → Overweight | — | $12.41 | $12.49 | +0.6% | +0.8% | +0.0% | +2.2% | -1.1% | -0.3% |
| Sep 23 | Barclays | Maintains | Overweight → Overweight | — | $14.07 | $14.17 | +0.7% | +2.6% | -3.9% | -1.6% | +0.5% | +4.3% |
| Sep 19 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $14.65 | $14.34 | -2.1% | +2.9% | -6.6% | +2.6% | -3.9% | -1.6% |
| Sep 19 | Stifel | Maintains | Buy → Buy | — | $14.65 | $14.34 | -2.1% | +2.9% | -6.6% | +2.6% | -3.9% | -1.6% |
| Jul 1 | Piper Sandler | Maintains | Neutral → Neutral | — | $14.43 | $14.46 | +0.2% | -2.3% | -0.6% | +0.9% | +0.6% | -2.0% |
| Jun 28 | Barclays | Maintains | Overweight → Overweight | — | $14.27 | $14.25 | -0.1% | +1.1% | -2.3% | -0.6% | +0.9% | +0.6% |
| May 13 | Piper Sandler | Maintains | Neutral → Neutral | — | $17.00 | $17.21 | +1.2% | +0.0% | +0.4% | -0.2% | -0.4% | +1.2% |
| May 9 | Barclays | Maintains | Overweight → Overweight | — | $16.89 | $16.82 | -0.4% | +1.8% | -1.2% | +0.0% | +0.4% | -0.2% |
| Mar 12 | Piper Sandler | Maintains | Neutral → Neutral | — | $16.02 | $16.09 | +0.4% | -1.6% | +0.9% | -1.0% | -0.2% | +0.4% |
| Feb 27 | Goldman Sachs | Maintains | Sell → Sell | — | $16.26 | $16.56 | +1.8% | +1.2% | -3.2% | -0.3% | +0.9% | +0.9% |
| Feb 27 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.26 | $16.56 | +1.8% | +1.2% | -3.2% | -0.3% | +0.9% | +0.9% |
| Feb 27 | Barclays | Maintains | Overweight → Overweight | — | $16.26 | $16.56 | +1.8% | +1.2% | -3.2% | -0.3% | +0.9% | +0.9% |
| Jan 17 | Goldman Sachs | Maintains | Sell → Sell | — | $15.13 | $14.90 | -1.5% | -2.2% | +0.0% | -1.4% | -0.4% | +1.2% |
| Jan 5 | Stifel | Upgrade | Hold → Buy | — | $14.55 | $15.46 | +6.3% | +6.2% | +0.6% | -0.9% | -1.3% | +1.8% |
| Dec 15 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $13.77 | $14.06 | +2.1% | -0.1% | -0.7% | +4.5% | -2.0% | +3.6% |
| Dec 7 | Stifel | Maintains | Hold → Hold | — | $12.87 | $13.06 | +1.5% | -0.8% | +0.2% | -0.7% | -0.2% | +7.6% |
| Nov 13 | Piper Sandler | Maintains | Neutral → Neutral | — | $10.68 | $10.68 | +0.0% | -1.2% | +7.5% | +0.6% | +0.7% | +2.9% |
| Nov 8 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.70 | $10.70 | +0.0% | +1.4% | -5.4% | +4.1% | -1.2% | +7.5% |
| Oct 30 | Stifel | Maintains | Hold → Hold | — | $8.85 | $8.89 | +0.5% | -0.5% | +0.0% | -2.0% | +8.6% | +2.6% |
| Aug 14 | Piper Sandler | Maintains | Neutral → Neutral | — | $12.17 | $12.12 | -0.4% | -1.4% | -1.9% | -2.0% | -0.7% | +1.4% |
| Aug 9 | Goldman Sachs | Maintains | Sell → Sell | — | $12.46 | $12.45 | -0.1% | -1.5% | -0.4% | -0.4% | -1.4% | -1.9% |
| Aug 8 | Goldman Sachs | Maintains | Sell → Sell | — | $12.12 | $12.15 | +0.2% | +2.8% | -1.5% | -0.4% | -0.4% | -1.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | Modi Rajeev A. | SEE REMARKS | Buy | 4,911 | $20.35 | $100K | 160,812 | +5.30% | +3.81% |
| May 15, 2026 | Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR | Buy | 4,971 | $20.09 | $100K | 171,971 | +5.30% | +3.81% |
8-K
Elanco Animal Health Incorporated -- 8-K Filing
May 27
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott Laboratories' appointment of a new executive effective April 1, 2026, signals potential strategic shifts in operations or leadership direction that could affect near-term stock performance and investor confidence in company management.
Mar 18
8-K
Elanco Animal Health Incorporated -- 8-K Filing
Elanco Animal Health achieved 9% organic constant currency revenue growth in Q4, marking its 10th consecutive quarter of underlying growth, signaling strong execution of its growth and innovation strategy.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Dodge & Cox | 68,944,100 | $1.6B | Reduced | Mar 2026 |
| 2 | Fmr Llc | 50,925,366 | $1.2B | Reduced | Mar 2026 |
| 3 | Primecap Management Co/ca/ | 45,840,956 | $1.1B | Reduced | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 22,637,357 | $542M | New | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 22,336,124 | $535M | New | Mar 2026 |
| 6 | Morgan Stanley | 16,573,216 | $375M | Reduced | Dec 2025 |
| 7 | Winslow Capital Management, Llc | 13,614,355 | $326M | New | Mar 2026 |
| 8 | Ubs Group Ag | 8,572,057 | $205M | Reduced | Mar 2026 |
| 9 | Invesco Ltd. | 8,141,172 | $195M | Added | Mar 2026 |
| 10 | Sei Investments Co | 5,650,393 | $135M | Added | Mar 2026 |
| 11 | Clearbridge Investments, Llc | 4,581,016 | $110M | Reduced | Mar 2026 |
| 12 | Citadel Advisors Llc | 4,387,127 | $105M | Added | Mar 2026 |
| 13 | Northern Trust Corp | 4,189,189 | $100M | Added | Mar 2026 |
| 14 | Bank Of New York Mellon Corp | 3,809,888 | $91M | Reduced | Mar 2026 |
| 15 | Barrow Hanley Mewhinney & Strauss Llc | 3,582,401 | $86M | Reduced | Mar 2026 |
| 16 | Capital World Investors | 3,408,331 | $82M | Added | Mar 2026 |
| 17 | Bank Of America Corp /de/ | 3,358,215 | $80M | Added | Mar 2026 |
| 18 | Jupiter Asset Management Ltd | 3,110,039 | $74M | Reduced | Mar 2026 |
| 19 | Douglas Lane & Associates, Llc | 2,847,152 | $68M | Reduced | Mar 2026 |
| 20 | Artemis Investment Management Llp | 2,841,535 | $68M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$12.02B
Enterprise Value
$15.42B
P/E (TTM)
-51.53x
Forward P/E
23.49x
PEG Ratio
0.29x
P/B
1.84x
P/S
2.55x
P/FCF
42.33x
EV/EBITDA
22.81x
Shares Out
496.4M
Financials (TTM)
Revenue
$4.71B
Net Income
-$232.0M
EBITDA
$676.0M
Free Cash Flow
$284.0M
Op Cash Flow
$560.0M
EPS Basic
$-0.47
EPS Diluted
$-0.47
EPS Forward
$1.03
Gross Margin
43.5%
Op Margin
5.3%
Net Margin
-4.9%
Balance Sheet
Total Assets
$13.36B
Total Liab.
$6.81B
Total Equity
$6.55B
Cash
$545.0M
LT Debt
$3.94B
Book Value/Sh
$13.19
Debt/Equity
0.61x
Current Ratio
2.17
Quick Ratio
1.08
Returns & Growth
ROE
-3.5%
ROA
-1.7%
ROIC
2.1%
Rev Growth YoY
+6.2%
EPS Growth YoY
-169.1%
Price Returns
2W
+10.2%
1M
+6.7%
3M
-9.6%
6M
+2.6%
12M
+77.6%
Technicals
52W High
$26.84
52W Low
$13.33
50d MA
$22.98
200d MA
$22.62
RSI (14)
52.30
ATR (14)
$1.07
Beta
1.88
Avg Volume
7.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$27.88
High
$30.00
Low
$22.00
Median
$29.50
Data updated apr 25, 2026 6:49am
· Source: financialmodelingprep.com